Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | Novel targets being explored in multiple myeloma and the value of CELMoDs

Andrew Cowan • 29 Sep 2023
IMS 2023
Multiple Myeloma Iberdomide Mezigdomide

Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, briefly discusses novel targets being explored in multiple myeloma, including FcRH5 and CD38, and further comments on the excitement surrounding the CELMoDs iberdomide and mezigdomide. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar

More from Andrew Cowan

Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs 1:24
Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs
Andrew Cowan • 29 Sep 2023
Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma 1:53
Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma
Andrew Cowan • 29 Sep 2023
Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb 1:47
Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb
Andrew Cowan • 29 Sep 2023
First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma 5:31
First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma
Andrew Cowan • 11 Dec 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals